FIELD: chemistry.
SUBSTANCE: invention relates to compounds of general structural formula:
or to pharmaceutically acceptable salts, where Z denotes -O- or -CH2- or -CH2-CH2-; X1 denotes a covalent bond or -O-; Y1 denotes a covalent bond or C1-C10 alkylene, provided that Y1 is a covalent bond only when X1 denotes a covalent bond; R1 denotes a) (C3-C7)cycloalkyl or b) phenyl or heteroaryl, which is a monovalent heteroatomatic monocyclic radical ring containing 1-2 heteroatoms, independently selected from nitrogen and sulphur, possibly substituted with 1-3 groups, independently selected from fluorine, chlorine, bromine, (C1-C6)alkyl or (C1-C6)-alkoxy; R2 denotes -OC(O)(NH2), -OC(O)(NHR9), -NHC(O)OR9, -C(O)R9, -C(O)(NH2), -C(O)(NHR9) or -NHC(O)H, where R9 denotes a linear or branched C1-C5 alkyl or a linear or branched (C1-C5)alkoxyalkyl; R3 denotes H, C1-C5 alkyl, -NHC(O)R10 or OH, where R10 denotes C1-C3 alkyl, provided that when R3 denotes -OH, X1 is not O and R2-Y1-X1 is not -OC(O)(NH2), -OC(O)(NHR9), -NHC(O)OR9 or -NHC(O)H; -Q denotes
, where N and N are bonded by bonds denoted by a wavy line; R4 denotes H; R5 and R6 independently denote: a) H, (C1-C10)alkyl, (C4-C10)cycloalkylalkyl, hydroxylated (C4-C10)cycloalkylalkyl, halo(C4-C10)cycloalkylalkyl, (C1-C2)alkyl(C4-C10)cycloakylalkyl, (C4-C10)bicycloalkyl(C1-C3)alkyl, (C1-C5)alkoxy(C1-C5)alkyl; or a saturated heterocyclyl(C1-C3)alkyl, where the saturated heterocyclic ring is selected from 5-, 6- or 7-member heterocyclic rings which contain 1 heteroatom independently selected from N and O; or b) phenyl(C1-C2)alkyl, phenoxymethyl, each of which is possibly with 1-3 groups independently selected from fluorine, chlorine, (C1-C3)alkyl, (C1-C3)alkoxy; provided that both R5 and R6 are not H; G denotes NH2 or NHR7; R7 denotes (C1-C6)alkyl; or R5 and R7 together denote -CH2, -(CH2)2 or -(CH2)3, possibly substituted with 1-2 groups independently selected from (C1-C8)-alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl(C1-C2)alkyl or (C1-C8)alkoxy. The invention also relates to compounds selected from the group, pharmaceutical compositions, a method for antagonising one or more aspartate proteases, as well as methods of treating aspartate protease-mediated disorders.
EFFECT: obtaining novel biologically active compounds having activity towards rennin.
35 cl, 33 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SULFONAMIDE DERIVATIVES AS GLYCOKINASE ACTIVATORS APPLICABLE FOR TREATING INSULIN-DEPENDENT DIABETES | 2006 |
|
RU2419624C2 |
| SULPHONAMIDETHIAZOLE PYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS, SUITABLE FOR TREATING TYPE-2 DIABETES | 2005 |
|
RU2412192C2 |
| FUNGICIDAL MIXTURES | 2008 |
|
RU2478287C2 |
| ALKYLSUPHINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | 2011 |
|
RU2605745C2 |
| PRODRUG 1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | 2003 |
|
RU2357962C2 |
| ACIDIFIED INDANYLAMINES AND THEIR USE AS PHARMACEUTICAL PREPARATIONS | 2002 |
|
RU2339614C2 |
| ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYLAMINES AND THEIR USING AS PHARMACEUTICAL PREPARATIONS | 2002 |
|
RU2301797C2 |
| NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
| DERIVATIVES OF BENZAMIDE, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION, PHARMACEUTICAL COMPOSITION AND METHOD FOR PROVISION OF INHIBITING ACTION IN RESPECT TO HDAC | 2003 |
|
RU2376287C2 |
| PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
